Format

Send to

Choose Destination
Oncotarget. 2015 Aug 28;6(25):21675-84.

Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancer.

Author information

1
Uro-oncology Research Group, CRUK Cambridge Institute, Cambridge, UK.
2
Department of Pathology, Centro Hospitalar do Porto, Porto, Portugal.
3
Department of Morphology, Institute of Biosciences, Sao Paulo State University (UNESP), Sao Paulo, Brazil.
4
Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
5
Molecular Diagnostics and Therapeutics Group, University College London, London, UK.
6
Statistics and Computational Biology Group, CRUK Cambridge Institute, Cambridge, UK.
7
Department of Urology, University of Cambridge, Department of Oncology, Addenbrooke's Hospital, Cambridge, UK.

Abstract

Monocarboxylate Transporter 2 (MCT2) is a major pyruvate transporter encoded by the SLC16A7 gene. Recent studies pointed to a consistent overexpression of MCT2 in prostate cancer (PCa) suggesting MCT2 as a putative biomarker and molecular target. Despite the importance of this observation the mechanisms involved in MCT2 regulation are unknown. Through an integrative analysis we have discovered that selective demethylation of an internal SLC16A7/MCT2 promoter is a recurrent event in independent PCa cohorts. This demethylation is associated with expression of isoforms differing only in 5'-UTR translational control motifs, providing one contributing mechanism for MCT2 protein overexpression in PCa. Genes co-expressed with SLC16A7/MCT2 also clustered in oncogenic-related pathways and effectors of these signalling pathways were found to bind at the SLC16A7/MCT2 gene locus. Finally, MCT2 knock-down attenuated the growth of PCa cells. The present study unveils an unexpected epigenetic regulation of SLC16A7/MCT2 isoforms and identifies a link between SLC16A7/MCT2, Androgen Receptor (AR), ETS-related gene (ERG) and other oncogenic pathways in PCa. These results underscore the importance of combining data from epigenetic, transcriptomic and protein level changes to allow more comprehensive insights into the mechanisms underlying protein expression, that in our case provide additional weight to MCT2 as a candidate biomarker and molecular target in PCa.

KEYWORDS:

castrate resistant disease; malignant phenotype; monocarboxylate transporter 2; prostate cancer

PMID:
26035357
PMCID:
PMC4673295
DOI:
10.18632/oncotarget.4328
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center